↓ Direkt till sidans innehåll
↓ Direkt till sidans sekundära innehåll (sidomenyn)

Tyck till om SwePub Sök här!

Träfflista för sökning "WFRF:(Poulsen P.) srt2:(2015-2019)"

Sökning: WFRF:(Poulsen P.) > (2015-2019)

Resultat 1-10 av 183

Sortera/gruppera träfflistan

Sortering: Träffar per sida:

Numrering	Referens	Omslagsbild	Hitta
1.	Jukema, JW, et al. (författare) Alirocumab in Patients With Polyvascular Disease and Recent Acute Coronary Syndrome: ODYSSEY OUTCOMES Trial 2019 Ingår i: Journal of the American College of Cardiology. - : Elsevier BV. - 1558-3597 .- 0735-1097. ; 74:9, s. 1167-1176 Tidskriftsartikel (refereegranskat)
2.	Ray, KK, et al. (författare) Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial 2019 Ingår i: The lancet. Diabetes & endocrinology. - 2213-8595 .- 2213-8587. ; 7:8, s. 618-628 Tidskriftsartikel (refereegranskat)
3.	Roe, MT, et al. (författare) Risk Categorization Using New American College of Cardiology/American Heart Association Guidelines for Cholesterol Management and Its Relation to Alirocumab Treatment Following Acute Coronary Syndromes 2019 Ingår i: Circulation. - : Ovid Technologies (Wolters Kluwer Health). - 1524-4539 .- 0009-7322. ; 140:19, s. 1578-1589 Tidskriftsartikel (refereegranskat)
4.	Steg, PG, et al. (författare) Effect of Alirocumab on Mortality After Acute Coronary Syndromes 2019 Ingår i: Circulation. - 1524-4539. ; 140:2, s. 103-112 Tidskriftsartikel (refereegranskat)
5.	Szarek, M, et al. (författare) Alirocumab Reduces Total Hospitalizations and Increases Days Alive and Out of Hospital in the ODYSSEY OUTCOMES Trial 2019 Ingår i: Circulation. Cardiovascular quality and outcomes. - : Ovid Technologies (Wolters Kluwer Health). - 1941-7705 .- 1941-7713. ; 12:11, s. e005858- Tidskriftsartikel (refereegranskat)
6.	Szarek, M, et al. (författare) Alirocumab Reduces Total Nonfatal Cardiovascular and Fatal Events: The ODYSSEY OUTCOMES Trial 2019 Ingår i: Journal of the American College of Cardiology. - : Elsevier BV. - 1558-3597 .- 0735-1097. ; 73:4, s. 387-396 Tidskriftsartikel (refereegranskat)
7.	Schwartz, GG, et al. (författare) Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome 2018 Ingår i: The New England journal of medicine. - : MASSACHUSETTS MEDICAL SOC. - 1533-4406 .- 0028-4793. ; 379:22, s. 2097-2107 Tidskriftsartikel (refereegranskat)
8.	Goodman, SG, et al. (författare) Effects of Alirocumab on Cardiovascular Events After Coronary Bypass Surgery 2019 Ingår i: Journal of the American College of Cardiology. - : Elsevier BV. - 1558-3597 .- 0735-1097. ; 74:9, s. 1177-1186 Tidskriftsartikel (refereegranskat)
9.	Ruilope, LM, et al. (författare) Design and Baseline Characteristics of the Finerenone in Reducing Cardiovascular Mortality and Morbidity in Diabetic Kidney Disease Trial 2019 Ingår i: American journal of nephrology. - : S. Karger AG. - 1421-9670 .- 0250-8095. ; 50:5, s. 345-356 Tidskriftsartikel (refereegranskat)abstract <b><i>Background:</i></b> Among people with diabetes, those with kidney disease have exceptionally high rates of cardiovascular (CV) morbidity and mortality and progression of their underlying kidney disease. Finerenone is a novel, nonsteroidal, selective mineralocorticoid receptor antagonist that has shown to reduce albuminuria in type 2 diabetes (T2D) patients with chronic kidney disease (CKD) while revealing only a low risk of hyperkalemia. However, the effect of finerenone on CV and renal outcomes has not yet been investigated in long-term trials. <b><i>Patients and</i></b> <b><i>Methods:</i></b> The Finerenone in Reducing CV Mortality and Morbidity in Diabetic Kidney Disease (FIGARO-DKD) trial aims to assess the efficacy and safety of finerenone compared to placebo at reducing clinically important CV and renal outcomes in T2D patients with CKD. FIGARO-DKD is a randomized, double-blind, placebo-controlled, parallel-group, event-driven trial running in 47 countries with an expected duration of approximately 6 years. FIGARO-DKD randomized 7,437 patients with an estimated glomerular filtration rate ≥25 mL/min/1.73 m<sup>2</sup> and albuminuria (urinary albumin-to-creatinine ratio ≥30 to ≤5,000 mg/g). The study has at least 90% power to detect a 20% reduction in the risk of the primary outcome (overall two-sided significance level α = 0.05), the composite of time to first occurrence of CV death, nonfatal myocardial infarction, nonfatal stroke, or hospitalization for heart failure. <b><i>Conclusions:</i></b> FIGARO-DKD will determine whether an optimally treated cohort of T2D patients with CKD at high risk of CV and renal events will experience cardiorenal benefits with the addition of finerenone to their treatment regimen. Trial Registration: EudraCT number: 2015-000950-39; ClinicalTrials.gov identifier: NCT02545049.
10.	Bousquet, J., et al. (författare) ARIA 2016 : Care pathways implementing emerging technologies for predictive medicine in rhinitis and asthma across the life cycle 2016 Ingår i: Clinical and Translational Allergy. - : Wiley. - 2045-7022. ; 6:1 Forskningsöversikt (refereegranskat)abstract The Allergic Rhinitis and its Impact on Asthma (ARIA) initiative commenced during a World Health Organization workshop in 1999. The initial goals were (1) to propose a new allergic rhinitis classification, (2) to promote the concept of multi-morbidity in asthma and rhinitis and (3) to develop guidelines with all stakeholders that could be used globally for all countries and populations. ARIA - disseminated and implemented in over 70 countries globally - is now focusing on the implementation of emerging technologies for individualized and predictive medicine. MASK [MACVIA (Contre les Maladies Chroniques pour un Vieillissement Actif)-ARIA Sentinel NetworK] uses mobile technology to develop care pathways for the management of rhinitis and asthma by a multi-disciplinary group and by patients themselves. An app (Android and iOS) is available in 20 countries and 15 languages. It uses a visual analogue scale to assess symptom control and work productivity as well as a clinical decision support system. It is associated with an inter-operable tablet for physicians and other health care professionals. The scaling up strategy uses the recommendations of the European Innovation Partnership on Active and Healthy Ageing. The aim of the novel ARIA approach is to provide an active and healthy life to rhinitis sufferers, whatever their age, sex or socio-economic status, in order to reduce health and social inequalities incurred by the disease.

Skapa referenser, mejla, bekava och länka

Länka till träfflistan

Resultat 1-10 av 183

Avgränsa träffmängd

Typ av publikation: tidskriftsartikel (180); forskningsöversikt (2); rapport (1)

Typ av innehåll: refereegranskat (182); övrigt vetenskapligt/konstnärligt (1)

Författare/redaktör: Ellert, Mattias (142); Strandberg, Jonas (141); Brenner, Richard (141); Ekelöf, Tord (141); Ripellino, Giulia (138); Sidebo, P. Edvin (137); visa fler...; Zwalinski, L. (136); Åkesson, Torsten (134); Bocchetta, Simona (134); Doglioni, Caterina (134); Hedberg, Vincent (134); Jarlskog, Göran (134); Kalderon, Charles (134); Lytken, Else (134); Mjörnmark, Ulf (134); Poulsen, Trine (134); Smirnova, Oxana (134); Moa, Torbjörn (131); Jon-And, Kerstin (131); Clement, Christophe (131); Milstead, David A. (131); Shaikh, Nabila W. (131); Sjölin, Jörgen (131); Wallängen, Veronica (131); Hellman, Sten (130); Ughetto, Michaël (130); Pöttgen, Ruth (127); Bokan, Petar (123); Gradin, P.O. Joakim (123); Bertoli, Gabriele (123); Silverstein, Samuel ... (122); Carney, Rebecca M. D ... (122); Mankinen, Katja (119); Molander, Simon (118); Lund-Jensen, Bengt (117); Gellerstedt, Karl (112); Kastanas, Konstatino ... (108); Kellermann, Edgar (107); Bergeås Kuutmann, El ... (107); Valdés Santurio, Edu ... (106); Ferrari, Arnaud, 197 ... (101); Viazlo, Oleksandr (96); Öhman, Henrik (89); Isacson, Max (85); Konya, Balazs (80); Sales De Bruin, Pedr ... (80); Bohm, Christian (78); Abulaiti, Yiming (77); Cribbs, Wayne A. (75); Åkerstedt, Henrik (75); visa färre...

Lärosäte: Lunds universitet (155); Uppsala universitet (150); Kungliga Tekniska Högskolan (141); Stockholms universitet (132); Karolinska Institutet (22); Chalmers tekniska högskola (6); visa fler...; Göteborgs universitet (5); Linköpings universitet (2); Umeå universitet (1); RISE (1); visa färre...

Språk: Engelska (183)

Forskningsämne (UKÄ/SCB): Naturvetenskap (154); Medicin och hälsovetenskap (17); Teknik (6)

År

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

Copyright © LIBRIS - Nationella bibliotekssystem
LIBRIS.kb.se

pil uppåt

Stäng

Kopiera och spara länken för att återkomma till aktuell vy